{
    "clinical_study": {
        "@rank": "45205", 
        "acronym": "GERD-SSc", 
        "arm_group": [
            {
                "arm_group_label": "Omeprazole plus alginic acid and placebo of domperidone", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Omeprazole plus domperidone and placebo of alginic acid", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators purposes are to define the prevalence of omeprazole resistance\n      gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc), to compare the efficacy\n      of omeprazole in combination with algycon versus omeprazole in combination with domperidone\n      on the severity of reflux symptoms in omeprazole resistant GERD in SSc, and to compare the\n      efficacy of omeprazole in combination with algycon versus omeprazole in combination with\n      domperidone on the frequency of symptoms in omeprazole- resistant GERD in SSc."
        }, 
        "brief_title": "Gastroesophageal Reflux Treatment in Scleroderma", 
        "condition": [
            "Gastroesophageal Reflux Disease", 
            "Systemic Sclerosis", 
            "Scleroderma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Scleroderma, Systemic", 
                "Scleroderma, Diffuse", 
                "Scleroderma, Localized", 
                "Gastroesophageal Reflux", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Phase 1 SSc patients who fit all inclusion and exclusion criteria will be eligible to\n        phase 1 study for evaluation the prevalence of omeprazole resistant-GERD\n\n        Inclusion criteria:\n\n          1. SSc patients aged between 18 and 65 years.\n\n          2. Clinically diagnosed as GERD and GERD-questionnaire score >3\n\n          3. Must not receive any proton pump inhibitor (PPI) or prokinetic drug within 2 weeks\n             before baseline evaluation\n\n        Exclusion criteria:\n\n          1. Pregnancy or lactation\n\n          2. Previous history of gastroesophageal surgery or endoscopic therapy due to severe\n             erosive esophagitis\n\n          3. Present of Barrett's esophagus\n\n          4. Bedridden and confined to no self-care\n\n          5. Evidence of active malignant disease\n\n          6. Present of uncontrolled or severe medical problems such as asthma, angina, hepatic or\n             renal diseases\n\n          7. Present of active infection that needs systemic antibiotic\n\n          8. Allergic history of omeprazole\n\n          9. Receiving prohibit co-medications that may have drug interaction or attenuate GERD\n             symptoms such as tetracycline, ferrous salt, digoxin, isoniacid, oral bisphosphonate\n\n        Phase 2 randomized parallel study SSc patients who fit all inclusion and exclusion\n        criteria will be eligible to phase 2 study.\n\n        Inclusion criteria:\n\n          1. SSc patients who completed the phase 1 study.\n\n          2. The subjects were defined as PPI-resistance.\n\n          3. The subject must be willing to continue phase 2 study.\n\n        Exclusion criteria:\n\n          1. Pregnancy\n\n          2. Present of uncontrolled or severe medical problems\n\n          3. Present of active infection\n\n          4. Allergic history of alginic acid or domperidone\n\n          5. Receiving prohibit co-medications that may have drug interaction or attenuate GERD\n             symptoms such as tetracycline, ferrous salt, digoxin, isoniacid, oral bisphosphonate\n\n          6. Chewing difficulty"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01878526", 
            "org_study_id": "GERD therapy in scleroderma", 
            "secondary_id": "PPI in SSc-GERD"
        }, 
        "intervention": [
            {
                "arm_group_label": "Omeprazole plus alginic acid and placebo of domperidone", 
                "description": "Algycon 1 tab chew tid after meal", 
                "intervention_name": "Alginic acid", 
                "intervention_type": "Drug", 
                "other_name": "Algycon"
            }, 
            {
                "arm_group_label": "Omeprazole plus alginic acid and placebo of domperidone", 
                "description": "placebo (for domperidone) 1 tab oral tid before meal", 
                "intervention_name": "placebo (for domperidone)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Omeprazole plus domperidone and placebo of alginic acid", 
                "description": "domperidone (10 mg) 1 tab oral tid before meal", 
                "intervention_name": "Domperidone", 
                "intervention_type": "Drug", 
                "other_name": "Molax"
            }, 
            {
                "arm_group_label": "Omeprazole plus domperidone and placebo of alginic acid", 
                "description": "placebo (for alginic acid) 1 tab chew tid after meal", 
                "intervention_name": "placebo (of alginic acid)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Domperidone", 
                "Omeprazole", 
                "Alginic acid", 
                "Proton Pump Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "gastroesophageal reflux disease", 
            "heart burn", 
            "regurgitation", 
            "systemic sclerosis", 
            "scleroderma", 
            "proton pump inhibitor", 
            "alginic acid", 
            "omeprazole", 
            "prokinetic"
        ], 
        "lastchanged_date": "September 24, 2013", 
        "location": {
            "contact": {
                "email": "fching@kku.ac.th", 
                "last_name": "Chingching Foocharoen, MD", 
                "phone": "6643363746"
            }, 
            "facility": {
                "address": {
                    "city": "Khon Kaen", 
                    "country": "Thailand", 
                    "zip": "40002"
                }, 
                "name": "123 Department of Medicine, Faculty of Medicine, Khon Kaen University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effectiveness of Domperidone Versus Alginic Acid Add on Omeprazole Therapy in Omeprazole Resistance Gastroesophageal Reflux in Systemic Sclerosis", 
        "overall_contact": {
            "email": "fching@kku.ac.th", 
            "last_name": "Chingching Foocharoen, MD", 
            "phone": "6643363746"
        }, 
        "overall_official": {
            "affiliation": "Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand", 
            "last_name": "Chingching Foocharoen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Thailand: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Changing severity of heart burn and regurgitation of SSc related omeprazole resistant GERD evaluated by visual analogue score (VAS)", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01878526"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Khon Kaen University", 
            "investigator_full_name": "Chingching Foocharoen", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "changing of frequency of symptoms in SSc related omeprazole resistant GERD evaluated by frequency scale for the symptoms of GERD (FSSG) and the quality of life which is evaluated by EQ-5DTM (by EuroQol Group)", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "the prevalence of omeprazole-resistant GERD in SSc after 4 weeks treatment with omeprazole", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Khon Kaen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Khon Kaen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}